. . . "Humans and other mammals"@en . . . "1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol"@en . . "Bevantololum"@en . "Yutaka Nomura, \"Process for preparation of bevantolol hydrochloride.\" U.S. Patent US5382689, issued December, 1974."@en . . . . " "@en . . . . . . . . "Bevantolol"@en . . . . . . . . "# Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2888789"@en . . "Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. By binding and antagonizing beta-1 receptors Bevantolol inhibits the normal normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure."@en . . . . "1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol"@en . "1-(3,4-Dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol"@en . . . . . . "approved"@en . "For the treatment of angina pectoris and hypertension."@en . "Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors."@en . "59170-23-9"@en . . . "(+-)-Bevantolol"@en . . "1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol"@en . . . . .